lanadelumab sold brand name takhzyro human monoclonal antibody class targets plasma kallikrein order promote prevention angioedema people hereditary lanadelumab approved united states first monoclonal antibody indicated prophylactic treatment prevent hereditary angioedema lanadelumab first treatment hereditary angioedema prevention made using cells within lab human common side effects include pain associated injection site reactions injection site bruising upper respiratory infection headache rash myalgia dizziness us food drug administration approved use lanadelumab august people years older either type type ii hereditary united states lanadelumab indicated prophylaxis hereditary angioedema phase iii randomized controlled trial examined efficacy safety lanadelumab preventing hereditary angioedema attacks common adverse events noted patients treated lanadelumab works binding enzyme within plasma kallikrein inhibit kallikrein protease functions cleave kininogen subsequently creating kininogen bradykinin potent people hereditary angioedema deficiency dysfunctional inhibitor enzyme regulates activity kallikreinkinin poor regulation inhibitor results increased levels kallikrein subsequent proteolysis proteolysis kininogen forces upscaled production bradykinin kininogen within increased bradykinin levels cause vasodilation increased vascular permeability succeeding angioedema pain associated hereditary angioedema phase clinical trials lanadelumab well tolerated reported reduce cleavage kininogen plasma participants hereditary angioedema decrease number participants experiencing attacks lanadelumabs approval united states spearheaded data presented phase multicenter double blind placebo controlled multiascendingdose trial lanadelumab given priority review breakthrough therapy orphan drug designations food drug phase help study evaluated efficacy safety lanadelumab drug produced dyax corp currently development participants studied period randomized doubleblind parallelgroup placebocontrolled participants randomized receive either lanadelumab treatment placebo subjects randomized receive lanadelumab randomized ratio receive doses either mg every weeks mg every weeks mg every participants medication statistically significant reduction hereditary angioedema attack rates per participants took lanadelumab every weeks less moderate severe study results proved three dosing regimens lanadelumab effective immune activation dostarlimab ibalizumab httpsenwikipediaorgwikilanadelumab